Published in Biotech Law Weekly, October 14th, 2005
Specifically, this U.S. patent, (Patent Number 6939376) covers the use of anti-restenotic, immuno-suppressive drugs including Everolimus, in combination with a biodegradable drug-release polymer coating on an endovascular stent. The patent was filed in April 2002, and is valid in the U.S. for 20 years from the filing date. The company has also filed for the same patent in Australia, Japan and Europe, which it is anticipating to receive.
''Intellectual assets are...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.